NASDAQ: COGT

Cogent Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for COGT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Cogent Biosciences, Inc. (NASDAQ: COGT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:31 UTC.

What Cogent Biosciences, Inc. does

Cogent Research and Therapeutics is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. The company's most advanced program is bezuclastinib, a tyrosine kinase inhibitor designed to treat Systemic Mastocytosis and gastrointestinal stromal tumors by targeting KIT mutations.

Summarized from Cogent Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-11
Return on equity	-31.88%
Debt/equity	0.42

Charts

Charts are in the appInteractive charts for COGT are available in Oxford Ledge.
Open COGT in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-05

2026-10-05DirectorStock Option (Right to Buy)Award759—
2026-08-31DirectorOption exercise41,927$236.5K
2026-08-31DirectorSale-42,349$1.57M

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC25,681,174$993.86M+11.1%
BlackRock, Inc.17,352,646$671.55M+62.2%
VANGUARD PORTFOLIO MANAGEMENT LLC8,072,411$312.40M+10.1%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2021-12-27Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2020-07-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2020-05-15Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
Seeking Alpha Feed2026-08-27
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
seekingalpha.com2026-06-14
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
globenewswire.com2026-05-30

Questions this page answers

What does Cogent Biosciences, Inc. do?

Cogent Research and Therapeutics is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases.

When did COGT last file with the SEC?

Cogent Biosciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:31 UTC. This page is also available as JSON at /api/data?ticker=COGT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for COGT and 5,000+ tickers.

Create a free account — keep COGT

For your agent

GET /api/data?ticker=COGT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt